ArticleFrontiers in bioinformatics2026
RLNSF-MDA: reliability-guided graph-regularized matrix factorization for immune-related miRNA-disease association prediction.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: MicroRNAs (miRNAs) regulate gene expression and are closely linked to the onset and progression of immune‑related diseases. Experimental discovery of disease‑associated miRNAs remains costly and time‑consuming, motivating computational prioritization. However, existing matrix‑completion and deep graph‑learning methods either underuse local biological neighborhood evidence or require complex multi‑view neural architectures. Methods: In this study, we present RLNSF‑MDA, a reliability‑guided graph‑regularized logistic matrix factorization framework for predicting potential miRNA-disease associations, with an emphasis on immune disease analysis. The method integrates disease semantic similarity; miRNA functional, semantic, and sequence similarities; and training‑only Gaussian interaction profile similarities through data‑driven reliability weights. It then combines multi‑scale neighborhood evidence, diffusion scores, low‑rank reconstruction features, and contrastive graph‑regularized latent factors. Results: On the HMDD v3.2 benchmark containing 788 miRNAs and 374 diseases, RLNSF‑MDA achieved an average accuracy of 0.8525, an AUC of 0.9194, and an AUPR of 0.9055 in five‑fold cross‑validation, and an average accuracy of 0.8569, an AUC of 0.9266, and an AUPR of 0.9197 in ten‑fold cross‑validation. Ablation experiments showed that the full model outperformed reduced feature combinations and training strategies, supporting the contribution of reliability‑guided fusion, side‑score construction, graph regularization, and contrastive ranking. Evidence from immune‑related case studies in dbDEMC V2.0 and miR2Disease further covered lupus nephritis, lymphoma, and leukemia, with 45, 47, and 47 confirmed miRNAs, respectively. Discussion: These results suggest that RLNSF‑MDA provides an effective and interpretable framework for prioritizing candidate miRNAs associated with immune‑related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.